[144] ARGAN INC SEC Filing
Rhea-AI Filing Summary
Form 144 Notice — ARGAN INC (AGX) This filing notifies a proposed sale of 4,698 shares of common stock on 09/29/2025 through Charles Schwab & Co., Inc. The filing states the shares were acquired via equity grants and exercised as options on 04/25/2024 (2,402 shares) and 06/12/2024 (2,296 shares). Aggregate market value of the proposed sale is reported as $1,281,708.36 and the total shares outstanding is listed as 13,811,575. The filer also discloses a prior sale of 2,621 shares on 07/29/2025 with gross proceeds of $617,586.23. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider filing discloses option-exercised shares and a planned smallblock sale; not obviously material to company capitalization.
The filer reports an upcoming sale of 4,698 shares acquired via equity grants and option exercises, with an aggregate market value of $1,281,708.36. Given the stated 13,811,575 shares outstanding, the notice documents routine insider liquidity rather than a large disposition. The filing also lists a prior sale of 2,621 shares for $617,586.23. These disclosures meet Rule 144 notice requirements and provide transparency about the source of the shares (issuer equity grants and option exercises) and the broker used.
TL;DR: The filing documents compliance with Rule 144 for an insider sale arising from equity compensation; procedural rather than governance-negative.
The notice indicates the securities were acquired from the issuer via equity grants and exercised by option on specified dates, and the seller affirms no undisclosed material adverse information. The use of a trading broker and the inclusion of a recent prior sale show adherence to public-disclosure norms for insider transactions. There is no information here indicating unusual governance concerns.